MIRM - Mirum Pharmaceuticals Inc Stock Price, Fair Value and News

$41.51+0.38 (+0.92%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

MIRM Price Action

Last 7 days

-2.2%

Last 30 days

-5.0%

Last 90 days

6.6%

Trailing 12 Months

33.5%

MIRM RSI Chart

MIRM Valuation

Market Cap

2.0B

Price/Earnings (Trailing)

-19.96

Price/Sales (Trailing)

6.49

EV/EBITDA

-26.52

Price/Free Cashflow

-906.58

MIRM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MIRM Fundamentals

MIRM Revenue

Revenue (TTM)

307.0M

Rev. Growth (Yr)

89.37%

Rev. Growth (Qtr)

16.05%

MIRM Earnings

Earnings (TTM)

-99.8M

Earnings Growth (Yr)

39.65%

Earnings Growth (Qtr)

42.22%

MIRM Profitability

Operating Margin

77.50%

EBT Margin

-31.91%

Return on Equity

-43.02%

Return on Assets

-14.94%

Free Cashflow Yield

-0.11%

MIRM Investor Care

Shares Dilution (1Y)

2.98%

Diluted EPS (TTM)

-2.06

MIRM Alerts

1 major insider sales recently.
JANUS HENDERSON GROUP PLC reported owning 9.4% of MIRM [2024-11-14]
Big jump in Revenue (Y/Y)
Big jump in Earnings (Y/Y)
Losses in recent quarter

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	224.0M	264.4M	307.0M	0
2023	95.8M	115.8M	144.7M	186.4M
2022	33.6M	48.1M	62.6M	77.1M
2021	0	0	0	19.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.

CEO	Mr. Christopher Peetz
WEBSITE	mirumpharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	213

Mirum Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Mirum Pharmaceuticals Inc? What does MIRM stand for in stocks?

MIRM is the stock ticker symbol of Mirum Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Mirum Pharmaceuticals Inc (MIRM)?

As of Fri Dec 20 2024, market cap of Mirum Pharmaceuticals Inc is 1.99 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MIRM stock?

You can check MIRM's fair value in chart for subscribers.

Is Mirum Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether MIRM is over valued or under valued. Whether Mirum Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Mirum Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MIRM.

What is Mirum Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, MIRM's PE ratio (Price to Earnings) is -19.96 and Price to Sales (PS) ratio is 6.49. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MIRM PE ratio will change depending on the future growth rate expectations of investors.